Efficacy of vitamin D supplementation on adult patients with non-alcoholic fatty liver disease: a single-center experience
Gastroenterology and Hepatology from Bed to Bench,
Aim: The aim of this study was to determine the efficacy of a 6-month intramuscular vitamin D supplementation in improving the liver parameters in adult patients with non-alcoholic fatty liver disease (NAFLD).
Background: The association between vitamin D level and NAFLD has not been determined.
Methods: A single-blinded non-randomized controlled trial was conducted in 80 NAFLD patients assigned to receive a monthly single intramuscular dose of 200,000 IU cholecalciferol/vitamin D3 (n= 40), or placebo (n= 40) for six months. Transient elastography for the measurement of controlled attenuation parameter (CAP) and liver stiffness measurements (LSM), as well as fibrosis 4 score (FIB4) and NAFLD fibrosis score (NFS) were performed.
Results: The mean serum 25(OH)D was significantly increased after six months of vitamin D treatment (16.31±10.23 Vs 39.37±11.99 ng/ml). In the vitamin D group, most vitamin D deficiency patients (70% deficiency, 10% insufficiency, and 20% sufficiency) had changed to be sufficient (7.5% deficiency, 5% insufficiency, and 87.5% sufficiency). On the other hand, the values of CAP (311.9±42.2 dB/m) and LSM (6.8±2 kPa) had significantly reduced after six months of supplementation (287.0 ±44.3dB/m and 6.1 ±1.1 kPa, respectively) with significantly higher mean CAP and LSM change from baseline in vitamin D group compared to the placebo group. Furthermore, the ALT and AST levels were significantly improved in Vitamin D group compared to the placebo group (P<0.05). Multivariate regression analysis showed that lower serum 25(OH)D level was the only significant predictor for NAFLD (OR=0.89, p=0.001) in this study.
Conclusion: A monthly single intramuscular dose of 200,000 IU cholecalciferol is effective in improving the laboratory and fibroscan parameters of the liver disease in NAFLD patients, which confirm a signiﬁcant relationship between vitamin D deficiency and the risk of NAFLD.
Keywords: Non-alcoholic fatty liver disease (NAFLD), vitamin D, Controlled attenuation parameter (CAP), Liver stiffness measurements (LSM).
(Please cite as: Gad AI, Elmedames MR, Abdelhai AR, Marei AM, Abdel-Ghani HA. Efficacy of vitamin D supplementation on adult patients with non-alcoholic fatty liver disease: a single-center experience. Gastroenterol Hepatol Bed Bench 2021;14(1):44-52).
- vitamin D
- and LSM
How to Cite
Eliades M, Spyrou E. Vitamin D: a new player in non-alcoholic fatty liver disease? World J Gastroenterol 2015; 21:1718-27.
Wang X, Li W, Zhang Y, Yang Y, Qin G. Association between vitamin D and non-alcoholic fatty liver disease/non-alcoholic steatohepatitis: results from a meta-analysis. Int J Clin Exp Med 2015;8:17221-34.
Younossi Z, Loomba R, Rinella M, Bugianesi E, Marchesini G, Neuschwander B, et al. Current and future therapeutic regimens for nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Hepatology 2018;68:361-71.
Sheth S, Gordon F, Chopra S. Nonalcoholic steatohepatitis. Ann Intern Med 1997;126:137-45.
Zúñiga S, Firrincieli D, Housset C, Chignard N. Vitamin D and the vitamin D receptor in liver pathophysiology. Clin Res Hepatol Gastroenterol 2011;35:295-302.
Buzzetti E, Pinzani M, and Tsochatzis E. The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD). Metabolism 2015;65:1038-48.
Younossi Z, Loomba R, Rinella M, Bugianesi E, Marchesini G, Neuschwander B, et al. et al. Diagnostic modalities for nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, and associated fibrosis. Hepatology 2018;68:349-60.
Angulo P. Obesity and Nonalcoholic Fatty Liver Disease. Nutr Rev 2008; 65:57-63.
Sharifi N, Amani R, Hajiani E, Cheraghian B. Does vitamin D improve liver enzymes, oxidative stress, and inflammatory biomarkers in adults with non-alcoholic fatty liver disease? A randomized clinical trial. Endocrine 2014;47:70-80.
Lorvand Amiri H, Agah S, Mousavi S, Hosseini A, Shidfar F. Regression of Non-Alcoholic Fatty Liver by Vitamin D Supplement: A Double-Blind Randomized Controlled Clinical Trial. Arch Iran Med 2016;19:631-8.
Barchetta I, Del Ben M, Angelico F, Di Martino M, Fraioli A, La Torre G, et al. No effects of oral vitamin D supplementation on non-alcoholic fatty liver disease in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial. BMC Med 2016;14:92.
Foroughi M, Maghsoudi Z, Askari G. The effect of vitamin D supplementation on blood sugar and different indices of insulin resistance in patients with non-alcoholic fatty liver disease (NAFLD). Iran. J. Nurs. Midwifery Res 2016;21:100.
Abramovitch S, Dahan-Bachar L, Sharvit E, Weisman Y, Tov AB, Brazowski E, et al. Vitamin D inhibits proliferation and profibrotic marker expression in hepatic stellate cells and decreases thioacetamide-induced liver fibrosis in rats. Gut 2011;60:1728-37.
Zhou Q, Hou F, Guo Z, Liang M, Wang G, Zhang X. 1,25-Dihydroxyvitamin D improved the free fatty-acid-induced insulin resistance in cultured C2C12 cells. Diabetes Metab Res Rev 2008;24:459-64.
Konstantakis C, Tselekouni P, Kalafateli M, Triantos C. Vitamin D deficiency in patients with liver cirrhosis. Ann Gastroenterol 2016;29:297-306.
Abramovitch S, Sharvit E, Weisman Y, Bentov A, Brazowski E, Cohen G, et al. Vitamin D inhibits proliferation and profibrotic marker expression in hepatic stellate cells and decreases thioacetamide induced liver fibrosis in rats. Gut 2014;60:1728-37.
Abramovitch S, Dahan-Bachar L, Sharvit E, Weisman Y, Ben Tov A, Brazowski E, et al. Vitamin D inhibits proliferation and profibrotic marker expression in hepatic stellate cells and decreases thioacetamide-induced liver fibrosis in rats. Gut 2011;60:1728-37.
Liangpunsakul S, Chalasani N. Serum Vitamin D Concentrations and Unexplained Elevation in ALT Among US Adults. Dig Dis Sci 2011;56:2124-9.
Holick M. High prevalence of vitamin D inadequacy and implications for health. Mayo Clin Proc 2006;81:353-73.
Bischoff-Ferrari H, Giovannucci E, Willett W, Dietrich T, Dawson-Hughes B. Estimation of optimal serum concentrations of 25-hydroxyvitamin D for multiple health outcomes. Am J Clin Nutr 2006;84:18-28.
Dawson-Hughes B, Heaney R, Holick M, Lips P, Meunier P, Vieth R. Estimates of optimal vitamin D status. Osteoporos Int 2005;16:713-6.
Angulo P, Hui JM, Marchesini G, Bugianesi E, George J, Farrell GC, et al. The NAFLD fibrosis score: A noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology 2007;45:846-54.
Sterling R, Lissen E, Clumeck N, Sola R, Cassia Correa M, Montaner J, et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology 2006;43:1317-25.
Yousif M, A. Sadek M, Farrag H, Selim F, Hamed E, Salama R. Associated vitamin D deficiency is a risk factor for the complication of HCV-related liver cirrhosis including hepatic encephalopathy and spontaneous bacterial peritonitis. Intern Emerg Med 2019;14:753-61.
Arteh J, Narra S, Nair S. Prevalence of Vitamin D Deficiency in Chronic Liver Disease. Dig Dis Sci 2010;55:624-2628.
Kitson M, Roberts S. D-livering the message: The importance of vitamin D status in chronic liver disease. J Hepatol 2012;57:897-909.
Lange C, Bojunga J, Ramos-Lopez E, Badenhoop K, Zeuzem S, Sarrazin C, et al. Vitamin D deficiency and a CYP27B1-1260 promoter polymorphism are associated with chronic hepatitis C and poor response to interferon-alfa based therapy. J Hepatol 2010;54:887-893.
Byrne C, Targher G. NAFLD: A multisystem disease. J Hepatol 2014;62:47-64.
Xiao G, Zhu S, Xiao X, Yan L, Yang J, Wu G. Comparison of laboratory tests, ultrasound, or magnetic resonance elastography to detect fibrosis in patients with nonalcoholic fatty liver disease: A meta‐analysis. Hepatology 2017;66:1486-501.
Vallet-Pichard A, Mallet V, Nalpas B, Verkarre V, Nalpas A, Dhalluin-Venier V, et al. FIB-4: An inexpensive and accurate marker of fibrosis in HCV infection. comparison with liver biopsy and fibrotest. Hepatology 2007;46:32-6.
Pacifico L,. Osborn J, Bonci E, Pierimarchi P, Chiesa C. Association between Vitamin D Levels and Nonalcoholic Fatty Liver Disease: Potential Confounding Variables. Mini-Reviews Med Chem 2019;19:310-32.
Papapostoli I, Lammert F, Caroline S. Effect of Short-Term Vitamin D Correction on Hepatic Steatosis as Quantified by Controlled Attenuation Parameter (CAP). J Gastrointestin Liver Dis 2016;25:175181.
Hariri M, Zohdi S. Effect of Vitamin D on Non-Alcoholic Fatty Liver Disease: A Systematic Review of Randomized Controlled Clinical Trials. Int J Prev Med 2019;10:14.
Eliades M, Spyrou E, Agrawal N, Lazo M, Brancati F, Potter J, et al. Meta-analysis: vitamin D and non-alcoholic fatty liver disease. Aliment Pharmacol Ther 2013;38:246-54.
Targher G, Bertolini L, Scala L, Cigolini M, Zenari L, Falezza G, et al. Associations between serum 25-hydroxyvitamin D3 concentrations and liver histology in patients with non-alcoholic fatty liver disease. Nutr Metab Cardiovasc Dis 2007;17:517-24.
Barchetta I, Angelico F, Del Ben M, Baroni M, Pozzilli P, Morini S, et al. Strong association between non alcoholic fatty liver disease (NAFLD) and low 25(OH) vitamin D levels in an adult population with normal serum liver enzymes. BMC Med 2011;9:85.
Manco M, Ciampalini P, Nobili V. Low levels of 25-hydroxyvitamin D3 in children with biopsy-proven nonalcoholic fatty liver disease. Hepatology 2010;51:2229.
- Abstract Viewed: 0 times
- PDF Downloaded: 0 times